Anti-VEGF Therapy for AMD

The VEGF Pathway

Vascular endothelial growth factor (VEGF) is the primary molecular target of intravitreal injections for wet AMD. VEGF-A is the only family member induced by hypoxia, and it governs both angiogenesis and vascular permeability: precisely the biology that drives choroidal neovascularization (CNV) in neovascular AMD. Blocking VEGF-A signaling removes the stimulus for new, leaky vessel growth. That is why anti-VEGF agents work across CNV subtypes (classic, occult, minimally classic) rather than just one.

Before Anti-VEGF: Laser & Photodynamic Therapy

Before anti-VEGF agents existed, wet AMD treatment options were limited and far less selective. Thermal laser photocoagulation could destroy a CNV lesion outright, but a subfoveal leak made that a poor trade: the laser cannot tell abnormal vessels from the fovea sitting on top of them, so treating the lesion meant burning the vision it was meant to save.

Photodynamic therapy (PDT) was the next step. It pairs a cold, non-thermal 689 nm laser with a light-activated drug, verteporfin (brand name Visudyne). Given intravenously, verteporfin accumulates preferentially in abnormal choroidal vessels; the laser then activates it, generating reactive oxygen species that occlude the neovascular membrane while sparing much more of the surrounding retina than a thermal burn would. PDT was a real gain in selectivity. It was still eclipsed once anti-VEGF agents arrived.

The Anti-VEGF Era

Pegaptanib (Macugen) was the first anti-VEGF agent approved for choroidal neovascularization, though newer drugs have long since supplanted it in practice. Ranibizumab (Lucentis) is the drug that established anti-VEGF as the dominant modality, backed by two pivotal randomized trials.

ANCHOR and MARINA

ANCHOR (2006) showed that ranibizumab was significantly superior to verteporfin PDT in predominantly classic CNV, displacing PDT as the standard of care for that lesion subtype. MARINA, run in parallel, showed ranibizumab's superiority over sham injection in minimally classic and occult CNV, the lesion subtypes PDT was poorly suited to treat at all. Together the two trials established ranibizumab, and by extension the anti-VEGF class, as effective across essentially the full spectrum of neovascular AMD lesion types rather than one subtype alone. The trial-to-lesion pairing (ANCHOR with classic CNV, MARINA with occult/minimally classic) is a frequently tested detail worth keeping straight.

Faricimab (Vabysmo) blocks a second target alongside VEGF-A: angiopoietin-2 (Ang-2). Neutralizing Ang-2 promotes vascular stability and dampens inflammation independent of VEGF blockade. In the TENAYA and LUCERNE trials, most faricimab-treated patients reached 12- or 16-week dosing intervals by week 48, with visual gains non-inferior to aflibercept dosed every 8 weeks. It was the first anti-VEGF agent approved with a validated second molecular target, not simply a longer-acting version of VEGF blockade alone.

Dry AMD: Oxidative Stress, AREDS, and Where Management Stands

Dry AMD's pathogenesis is closely tied to oxidative stress in the retina. Superoxide dismutase (SOD), an antioxidant enzyme with both mitochondrial and cytoplasmic isoforms, shows polymorphisms and altered activity implicated in AMD. The RPE carries comparatively more vitamin E than other ocular cells, built in specifically to quench photo-oxidative free-radical chain reactions and blunt that same damage pathway.

This biology is the rationale behind the AREDS and AREDS2 trials. AREDS (Age-Related Eye Disease Study) established that antioxidant and zinc supplementation lowers the risk of progressing to advanced AMD. AREDS2 refined the formulation (vitamins C and E, zinc, copper, lutein, and zeaxanthin) for patients with intermediate AMD, or advanced AMD in one eye only, cutting progression risk by roughly 25%. It is not indicated for every patient with any drusen, and it is not a treatment for wet AMD. It is a progression-risk-reduction strategy for dry disease, aimed at protecting a still-unaffected or less-affected fellow eye.

Still, no definitive treatment exists for dry AMD itself. Roughly 90% of AMD, mostly the dry form, remains untreatable in the sense of reversing or halting established disease, though vitamins can slow progression as above. Newer complement inhibitors, pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay), were FDA-approved in 2023 for geographic atrophy specifically, building on the same complement-pathway genetics (CFH) behind AMD's heritability. Even with these approvals, no treatment restores tissue already lost to atrophy.

Related Topics

Continue exploring Retina & Vitreous: